Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EBITDA (2016 - 2025)

Historic EBITDA for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$2.1 million.

  • Marker Therapeutics' EBITDA rose 1096.5% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.9 million, marking a year-over-year decrease of 4583.83%. This contributed to the annual value of -$11.1 million for FY2024, which is 2374.95% up from last year.
  • As of Q3 2025, Marker Therapeutics' EBITDA stood at -$2.1 million, which was up 1096.5% from -$4.3 million recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' EBITDA peaked at -$2.1 million during Q3 2025, and registered a low of -$9.8 million during Q1 2022.
  • Over the past 4 years, Marker Therapeutics' median EBITDA value was -$3.9 million (recorded in 2024), while the average stood at -$4.0 million.
  • As far as peak fluctuations go, Marker Therapeutics' EBITDA soared by 5600.21% in 2023, and later crashed by 8461.49% in 2025.
  • Quarter analysis of 4 years shows Marker Therapeutics' EBITDA stood at -$3.0 million in 2022, then grew by 3.32% to -$2.9 million in 2023, then tumbled by 31.44% to -$3.9 million in 2024, then surged by 44.66% to -$2.1 million in 2025.
  • Its last three reported values are -$2.1 million in Q3 2025, -$4.3 million for Q2 2025, and -$4.6 million during Q1 2025.